WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)

This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in patients with advanced solid tumors complicated by malignant pleural or peritoneal effusions who have failed standard of care.

NCT Number	NCT07615894
Lead Sponsor	WestVac Biopharma Co., Ltd.
Conditions	Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
Enrollment	9 participants
Start Date	2026-06-01
Primary Completion	2028-01-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-29